11 March 2020 - RadioMedix and its commercial partner Curium announced the U.S. FDA has granted copper Cu 64 dotatate injection a priority review.
Copper Cu 64 dotatate is a PET diagnostic agent intended for somatostatin receptor expressing neuroendocrine tumours.
Curium is preparing to launch copper Cu 64 dotatate in Q3 of this year.